BCBSA is a national federation of 36 Blue Cross and Blue Shield (BCBS) companies. The report summarized that sufficient evidence exists to determine that hypoglossal nerve stimulation results in a meaningful improvement in the net health outcome for patients meeting the following selection criteria, which are based on information from clinical study populations and clinical expert opinion: "This positive assessment demonstrates the strength of the clinical evidence for Inspire therapy and is an important step forward in securing coverage from health insurance providers in the BCBS affiliate network," says Tim Herbert, president and CEO of Inspire Medical Systems, in a release. "This positive Evidence Street assessment for Inspire therapy will provide us with key support in our ongoing discussions with BCBS companies that relate to positive coverage decisions in the future.